Treatment & Research Archives

May 25, 2023

ASH 2022: Dr. Richard Furman on Acalabrutinib for Treatment of Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

Follow-up results from a phase 1/2 trial of acalabrutinib in CLL/SLL patients further confirm that acalabrutinib is safe & effective.

May 25, 2023

ASH 2022: Dr. Lindsey Roeker on Comparing Acalabrutinib and Ibrutinib in the Real World

Patients with acalabrutinib had lower discontinuation rates and a prolonged time to discontinuation compared to pts treated with ibrutinib.

May 25, 2023

ASH 2022: Dr. Bill Wierda on Pharmacological Profiling of Cells from Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Pirtobrutinib

Pirtobrutinib can extend the benefits of Bruton tyrosine kinase (BTKi) in patients with CLL/SLL who are resistant to covalent BTKi

May 2, 2023

ASH 2022: Dr. Mazyar Shadman on Enitociclib, a CDK9 Inhibitor, for Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

We discuss enitociclib, an experimental CDK9 inhibitor in development for treating NHL and CLL.

May 2, 2023

ASH 2022: Dr. Farrukh Awan on Real-World Treatment Patterns Among Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) who Have Received 2+ Lines of Therapy

A study that used real-world data to see what treatments are being given to patients with CLL/SLL who have received 2+ lines of therapy

April 26, 2023

Observational Study of Cardiac Arrhythmia in Subjects Treated With BTK Inhibitors

BTK inhibitors have revolutionized the care of CLL/SLL patients and profoundly improved outcomes

April 26, 2023

ASH 2022: Dr. Bill Wierda on Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia

The combination of ibrutinib plus venetoclax is an effective first-line treatment for high-risk chronic lymphocytic leukemia (CLL)

April 26, 2023

ASH 2022: Dr. Neil Kay on Combination Therapies for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

We discuss combination therapies for CLL and SLL, focusing on the combination of ibrutinib plus venetoclax.

April 26, 2023

ASH 2022: Dr. Bill Wierda on Acalabrutinib as a First-line Therapy for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

Final data from a phase 1/2 clinical trial with six years of follow-up show that first-line acalabrutinib produces high response rates and rapid, durable responses in patients with CLL

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Treatment & Research

ASH 2022: Dr. Richard Furman on Acalabrutinib for Treatment of Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

ASH 2022: Dr. Lindsey Roeker on Comparing Acalabrutinib and Ibrutinib in the Real World

ASH 2022: Dr. Bill Wierda on Pharmacological Profiling of Cells from Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Pirtobrutinib

ASH 2022: Dr. Mazyar Shadman on Enitociclib, a CDK9 Inhibitor, for Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

ASH 2022: Dr. Farrukh Awan on Real-World Treatment Patterns Among Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) who Have Received 2+ Lines of Therapy

Observational Study of Cardiac Arrhythmia in Subjects Treated With BTK Inhibitors

ASH 2022: Dr. Bill Wierda on Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia

ASH 2022: Dr. Neil Kay on Combination Therapies for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

ASH 2022: Dr. Bill Wierda on Acalabrutinib as a First-line Therapy for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT US

CONTACT